Olanzapine-induced myoclonic status

Clinical Neuropharmacology

Volumn 28, Issue 3, 2005, Pages 145-147

  Camacho, Ana ^a   García Navarro, Magdalena ^a   Martínez, Begoña ^a   Villarejo, Alberto ^b   Pomares, Eva ^a  

^a Clinica Mediterranea de Neurociencias   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Alzheimer disease; Antipsychotics; Myoclonus; Olanzapine; Status epilepticus

Indexed keywords

CITALOPRAM; CLOZAPINE; DONEPEZIL; HALOPERIDOL; OLANZAPINE; QUETIAPINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; ALZHEIMER DISEASE; ARTICLE; CASE REPORT; DOSE RESPONSE; ELECTROENCEPHALOGRAM; FEMALE; HIGH RISK PATIENT; HUMAN; MYOCLONUS; PRIORITY JOURNAL; SEIZURE; SEIZURE THRESHOLD;

ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROENCEPHALOGRAPHY; FEMALE; HALOPERIDOL; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; MYOCLONUS; PSYCHIATRIC STATUS RATING SCALES; STATUS EPILEPTICUS;

EID: 21544444966     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wnf.0000165351.10841.fa     Document Type: Article

References (19)

1. Fulton B, Goa KL. Olanzapine: a review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs. 1997;53:281-298.
2. Devinsky O, Honigfeld G, Patin J. Clozapine-related seizures. Neurology. 1991;41:369-371.
3. Beasley CM Jr, Tollefson GD, Tran PV. Safety of olanzapine. J Clin Psychiatry. 1997;58:13-17.
4. Amann BL, Pogarell O, Mergl R, et al. EEG abnormalities associated with antipsychotics: a comparison of quetiapine, olanzapine, haloperidol and healthy subjects. Hum Psychopharmacol. 2003;18:641-646.
5. Centorrino F, Price BH, Turtle M, et al. EEG abnormalities during treatment with typical and atypical antipsychotics. Am J Psychiatry. 2002; 159:109-115.
6. Woolley J, Smith S. Lowered seizure threshold on olanzapine. Br J Psychiatry. 2001;178:85-86.
7. Bonelli RM. Olanzapine-associated seizure. Ann Pharmacother. 2003;37: 149-150.
8. Lee JW, Crismon ML, Dorson PG. Seizure associated with olanzapine. Ann Pharmacother. 1999;33:554-556.
9. Hedges DW, Jeppson KG. New-onset seizure associated with quetiapine and olanzapine. Ann Pharmacother. 2002;36:437-439.
10. Deshauer D, Alburquerque J, Aida M, et al. Seizures caused by possible interaction between olanzapine and clomipramine. J Clin Psychopharmacol. 2000;20:283-284.
11. Wyderski RJ, Starret WG, Abou-Saif A. Fatal status epilepticus associated with olanzapine therapy. Ann Pharmacother. 1999;33:787-789.
12. Malow BA, Reese KB, Sato S, et al. Spectrum of EEG abnormalities during clozapine treatment. Electroencephalogr Clin Neurophysiol. 1994; 91:205-211.
13. Stevens JR, Denney D, Szot P. Kindling with clozapine: behavioural and molecular consequences. Epilepsy Res. 1996;26:295-304.
14. Gordon MF. Toxin and drug-induced myoclonus. Adv Neurol. 2002;89: 49-76.
15. Jiménez-Jiménez FJ, Puertas I, de Toledo-Heras M. Drug-induced myoclonus: frequency, mechanisms and management. CNS Drugs. 2004; 18:93-104.
16. Hauser WA, Morris ML, Heston LL, et al. Seizures and myoclonus in patients with Alzheimer's disease. Neurology. 1986;36:1226-1230.
17. Brosen K, Naranjo CA. Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. Eur Neuropsychopharmacol. 2001;11:275-283.
18. Babic T, Zurak N. Convulsions induced by donepezil. J Neurol Neurosurg Psychiatry. 1999;66:410.
19. Street J, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioural symptoms in patients with Alzheimer's disease in nursing care facilities. A double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry. 2000;57:968-976.